New opportunities from the cancer metabolome

Omran Abuaboud, Robert H Weiss

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

BACKGROUND: Metabolomics, the study of all metabolites produced in the body, which often includes flora and drug metabolites, is the omics approach that can be considered most closely related to a patient's phenotype. Metabolomics has a great and largely untapped potential in the field of oncology, and the analysis of the cancer metabolome to identify biofluid markers and novel druggable targets can now be undertaken in many research laboratories. CONTENT: The cancer metabolome has been used to identify and begin to evaluate potential biomarkers and therapeutic targets in a variety of malignancies, including breast, prostate, and kidney cancer. We discuss the several standard techniques for metabolite separation and identification, with their potential problems and drawbacks. Validation of biomarkers and targets may entail intensive use of labor and technology and generally requires a large number of study participants as well as laboratory validation studies. The field of pharmacometabolomics, in which specific therapies are chosen on the basis of a patient's metabolomic profile, has shown some promise in the translation of metabolomics into the arena of personalized medicine. SUMMARY: The relatively new approach using metabolomics has just begun to enter the mainstream of cancer diagnostics and therapeutics. As this field advances, metabolomics will take its well-deserved place next to genomics, transcriptomics, and proteomics in both clinical and basic research in oncology.

Original languageEnglish (US)
Pages (from-to)138-146
Number of pages9
JournalClinical Chemistry
Volume59
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Metabolomics
Metabolome
Metabolites
Neoplasms
Oncology
Biomarkers
Precision Medicine
Kidney Neoplasms
Validation Studies
Research laboratories
Genomics
Research
Proteomics
Medicine
Prostatic Neoplasms
Therapeutics
Personnel
Breast Neoplasms
Technology
Phenotype

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

New opportunities from the cancer metabolome. / Abuaboud, Omran; Weiss, Robert H.

In: Clinical Chemistry, Vol. 59, No. 1, 01.2013, p. 138-146.

Research output: Contribution to journalArticle

Abuaboud, Omran ; Weiss, Robert H. / New opportunities from the cancer metabolome. In: Clinical Chemistry. 2013 ; Vol. 59, No. 1. pp. 138-146.
@article{b3af66ebecb84b08b3b44fa6e5a66d7c,
title = "New opportunities from the cancer metabolome",
abstract = "BACKGROUND: Metabolomics, the study of all metabolites produced in the body, which often includes flora and drug metabolites, is the omics approach that can be considered most closely related to a patient's phenotype. Metabolomics has a great and largely untapped potential in the field of oncology, and the analysis of the cancer metabolome to identify biofluid markers and novel druggable targets can now be undertaken in many research laboratories. CONTENT: The cancer metabolome has been used to identify and begin to evaluate potential biomarkers and therapeutic targets in a variety of malignancies, including breast, prostate, and kidney cancer. We discuss the several standard techniques for metabolite separation and identification, with their potential problems and drawbacks. Validation of biomarkers and targets may entail intensive use of labor and technology and generally requires a large number of study participants as well as laboratory validation studies. The field of pharmacometabolomics, in which specific therapies are chosen on the basis of a patient's metabolomic profile, has shown some promise in the translation of metabolomics into the arena of personalized medicine. SUMMARY: The relatively new approach using metabolomics has just begun to enter the mainstream of cancer diagnostics and therapeutics. As this field advances, metabolomics will take its well-deserved place next to genomics, transcriptomics, and proteomics in both clinical and basic research in oncology.",
author = "Omran Abuaboud and Weiss, {Robert H}",
year = "2013",
month = "1",
doi = "10.1373/clinchem.2012.184598",
language = "English (US)",
volume = "59",
pages = "138--146",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - New opportunities from the cancer metabolome

AU - Abuaboud, Omran

AU - Weiss, Robert H

PY - 2013/1

Y1 - 2013/1

N2 - BACKGROUND: Metabolomics, the study of all metabolites produced in the body, which often includes flora and drug metabolites, is the omics approach that can be considered most closely related to a patient's phenotype. Metabolomics has a great and largely untapped potential in the field of oncology, and the analysis of the cancer metabolome to identify biofluid markers and novel druggable targets can now be undertaken in many research laboratories. CONTENT: The cancer metabolome has been used to identify and begin to evaluate potential biomarkers and therapeutic targets in a variety of malignancies, including breast, prostate, and kidney cancer. We discuss the several standard techniques for metabolite separation and identification, with their potential problems and drawbacks. Validation of biomarkers and targets may entail intensive use of labor and technology and generally requires a large number of study participants as well as laboratory validation studies. The field of pharmacometabolomics, in which specific therapies are chosen on the basis of a patient's metabolomic profile, has shown some promise in the translation of metabolomics into the arena of personalized medicine. SUMMARY: The relatively new approach using metabolomics has just begun to enter the mainstream of cancer diagnostics and therapeutics. As this field advances, metabolomics will take its well-deserved place next to genomics, transcriptomics, and proteomics in both clinical and basic research in oncology.

AB - BACKGROUND: Metabolomics, the study of all metabolites produced in the body, which often includes flora and drug metabolites, is the omics approach that can be considered most closely related to a patient's phenotype. Metabolomics has a great and largely untapped potential in the field of oncology, and the analysis of the cancer metabolome to identify biofluid markers and novel druggable targets can now be undertaken in many research laboratories. CONTENT: The cancer metabolome has been used to identify and begin to evaluate potential biomarkers and therapeutic targets in a variety of malignancies, including breast, prostate, and kidney cancer. We discuss the several standard techniques for metabolite separation and identification, with their potential problems and drawbacks. Validation of biomarkers and targets may entail intensive use of labor and technology and generally requires a large number of study participants as well as laboratory validation studies. The field of pharmacometabolomics, in which specific therapies are chosen on the basis of a patient's metabolomic profile, has shown some promise in the translation of metabolomics into the arena of personalized medicine. SUMMARY: The relatively new approach using metabolomics has just begun to enter the mainstream of cancer diagnostics and therapeutics. As this field advances, metabolomics will take its well-deserved place next to genomics, transcriptomics, and proteomics in both clinical and basic research in oncology.

UR - http://www.scopus.com/inward/record.url?scp=84872028171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872028171&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2012.184598

DO - 10.1373/clinchem.2012.184598

M3 - Article

C2 - 23150057

AN - SCOPUS:84872028171

VL - 59

SP - 138

EP - 146

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -